457 related articles for article (PubMed ID: 9627590)
1. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
3. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
5. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
[TBL] [Abstract][Full Text] [Related]
15. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
Christy C; Pichichero ME; Reed GF; Decker MD; Anderson EL; Rennels MB; Englund JA; Edwards KM; Steinhoff MC
Pediatrics; 1995 Sep; 96(3 Pt 2):584-7. PubMed ID: 7659481
[TBL] [Abstract][Full Text] [Related]
16. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
17. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines.
Giuliano M; Mastrantonio P; Giammanco A; Bottone M; Piscitelli A; Di Tommaso S; Robino L; Basso F; D'Orazio P
Dev Biol Stand; 1997; 89():275-8. PubMed ID: 9272360
[TBL] [Abstract][Full Text] [Related]
18. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
19. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
